Replies to post #222171 on Biotech Values

[dewophile]

If the drugs can be combined w PD-1s effectively (easier said than done) then that could transform a drug from "incremental" to "innovative". It also has the added commercial benefit of setting the PD-1 apart from the pack so could really lead to a large premium in any BD deal.